Master AI & Machine Learning for 50% Off
Go under the hood of AI — neural networks, real-world applications & more. Designed by UNSW experts.
Enroll Now
Explore the intersection of artificial intelligence and pharmacy practice within the Indian regulatory and clinical context through this course designed for pharmacy students and practitioners navigating India's evolving digital health landscape. Apply the NLEM Verification Checklist to audit AI-generated dispensing and pricing outputs, identify high-risk AI compliance patterns specific to Indian pharmacy settings, and understand the pharmacist's criminal liability under the Drugs & Cosmetics Act and Essential Commodities Act when AI is involved in prescription processing.
Develop the skills to critically evaluate AI-generated drug information against CDSCO approvals, Indian Pharmacopoeia standards, and PvPI adverse drug reaction data. Recognize AYUSH-allopathic interaction risks that Western-trained AI systems frequently overlook, and apply the PvPI reporting framework with independent clinical judgment when assessing AI-normalized adverse events.
Understand the pharmacist's professional liability across India's multi-layered legal framework for AI-assisted practice, apply a structured AI governance framework to evaluate tools for adoption in Indian pharmacy settings, and build a career resilience strategy aligned with ABDM digital health integration and the broader transformation of India's pharmacy sector.
Engage with AI tools appropriately within PCI curriculum requirements and Indian academic integrity frameworks, identify five India-specific AI failure modes most likely to mislead pharmacy students, and formulate a progressive career readiness strategy that positions you as an AI-literate practitioner in India's competitive pharmacy workforce.
Consolidate learning through four 3D animated Indian pharmacy scenarios that require integrated application of NLEM verification, CDSCO compliance, AYUSH safety screening, and PvPI reporting, while identifying AI errors with direct regulatory and patient safety consequences.
